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Gene therapy approaches are being deployed to treat recessive genetic disorders by
restoring the expression of mutated genes. However, the feasibility of these approaches for
dominantly inherited diseases — where treatment may require reduction in the expression
of a toxic mutant protein resulting from a gain-of-function allele — is unclear. Here we show
the efficacy of allele-specific RNAi as a potential therapy for Charcot-Marie-Tooth disease
type 2D (CMT2D), caused by dominant mutations in glycyl-tRNA synthetase (GARS). A de
novo mutation in GARS was identified in a patient with a severe peripheral neuropathy, and
a mouse model precisely recreating the mutation was produced. These mice developed a
neuropathy by 3–4 weeks of age, validating the pathogenicity of the mutation. RNAi
sequences targeting mutant GARS mRNA, but not wild-type, were optimized and then
packaged into AAV9 for in vivo delivery. This almost completely prevented the neuropathy
in mice treated at birth. Delaying treatment until after disease onset showed modest benefit,
though this effect decreased the longer treatment was delayed. These outcomes were
reproduced in a second mouse model of CMT2D using a vector specifically targeting that
allele. The effects were dose dependent, and persisted for at least 1 year. Our findings
demonstrate the feasibility of AAV9-mediated allele-specific knockdown and provide proof
of concept for gene therapy approaches for dominant neuromuscular diseases.
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Gene therapy approaches are being deployed to treat recessive genetic disorders by restoring the expression of mutated
genes. However, the feasibility of these approaches for dominantly inherited diseases — where treatment may require
reduction in the expression of a toxic mutant protein resulting from a gain-of-function allele — is unclear. Here we show the
efficacy of allele-specific RNAi as a potential therapy for Charcot-Marie-Tooth disease type 2D (CMT2D), caused by dominant
mutations in glycyl-tRNA synthetase (GARS). A de novo mutation in GARS was identified in a patient with a severe peripheral
neuropathy, and a mouse model precisely recreating the mutation was produced. These mice developed a neuropathy by 3–4
weeks of age, validating the pathogenicity of the mutation. RNAi sequences targeting mutant GARS mRNA, but not wildtype, were optimized and then packaged into AAV9 for in vivo delivery. This almost completely prevented the neuropathy
in mice treated at birth. Delaying treatment until after disease onset showed modest benefit, though this effect decreased
the longer treatment was delayed. These outcomes were reproduced in a second mouse model of CMT2D using a vector
specifically targeting that allele. The effects were dose dependent, and persisted for at least 1 year. Our findings demonstrate
the feasibility of AAV9-mediated allele-specific knockdown and provide proof of concept for gene therapy approaches for
dominant neuromuscular diseases.

Introduction

Personalized medicine seeks to provide optimized treatments
for individuals based on the molecular characteristics of their
specific disease. For example, cancer treatments are customized to the genetics of the patient and the tumor (1, 2). However,
developing personalized treatments for rare Mendelian disorders is challenging, and only about 5% of the more than 6800
recognized rare diseases have approved therapies (https://
www.genome.gov/2 7 53 1963/faq-about-rare- diseases/).
Often, even when a disease gene is defined, the pathological
impacts of specific genetic lesions may be uncertain or variable. In such cases, animal models recapitulating molecular
lesions offer a means for validating the causality of new human
mutations, and can serve as surrogates in preclinical therapeutic development (3, 4).
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Gene therapy is a potentially powerful approach for treating
rare genetic disorders, as it can precisely address the primary
cause of these conditions (5). Gene therapy approaches are now
in the clinic to treat recessive loss-of-function conditions by
restoring the expression of the mutated genes (6, 7). However,
the feasibility of gene silencing therapy to treat dominantly
inherited, monoallelic mutations — where treatment may
require reduction in the expression of a toxic mutant protein
resulting from a gain-of-function allele — is unclear. To date,
ClinicalTrials.gov lists only 2 phase I/II studies designed to
test the safety of vector-expressed inhibitory RNAs in humans,
and both were indicated for suppressing chronic hepatitis virus
infection (NCT01899092 and NCT02315638). Thus, RNAibased therapy is still an emerging field.
Here, we combine precision models of a dominant inherited
neuropathy — Charcot-Marie-Tooth disease type 2D (MIM
#601472), caused by mutations in glycyl-tRNA synthetase (GARS)
(MIM #600287) — with allele-specific knockdown by viral vector–
delivered gene therapy to demonstrate the effectiveness of this
strategy. We designed our treatment for a single patient, but this
sets an important precedent, as 90% of inherited peripheral
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neuropathies — as well as the majority of familial amyotrophic
lateral sclerosis cases — are inherited in an autosomal dominant
manner (8, 9).
Charcot-Marie-Tooth disease type 2D (CMT2D) is a progressive, inherited axonal neuropathy caused by dominant mutations in GARS, encoding glycyl-tRNA synthetase (10). Mutations in GARS also cause a purely motor neuropathy, clinically
designated as distal spinal muscular atrophy type V, but this is
allelic with CMT2D (11). There is no treatment for CMT2D or
any other form of inherited peripheral neuropathy. To date, at
least 19 individual mutations in GARS have been identified in
patients with CMT2D (12), all of which result in single–amino
acid changes in different functional domains of GARS (10,
13–16). However, the mechanisms through which mutant forms
of GARS cause axon degeneration remain unclear, limiting the
development of a small-molecule therapy.
Most disease-associated GARS variants cause impaired enzymatic activity in the charging of glycine onto tRNAGly in vitro and/
or decreased cellular viability in yeast complementation assays,
consistent with a loss-of-function effect (17, 18). However, proteinnull alleles in mice and humans do not cause dominant neuropathy, ruling out haploinsufficiency and suggesting a dominantnegative (antimorph) mechanism (19–22). Furthermore, transgenic overexpression of wild-type (WT) GARS does not rescue
the neuropathy in mouse models, suggesting that mutant forms of
GARS adopt a toxic gain-of-function (neomorph) activity that the
WT protein cannot outcompete (20). One proposed neomorphic
mechanism involves the abnormal binding of mutant GARS to
the developmental receptor neuropilin-1 (NRP1). This interaction
competes with the normal binding of vascular endothelial growth
factor (VEGF), an endogenous ligand of NRP1 (23).
Together, these data support a model in which suppression
of the mutant allele of GARS should be of therapeutic benefit,
whereas enhancing normal GARS function is ineffective. To
achieve this suppression, we developed a gene therapy strategy to reduce the levels of mutant Gars transcripts through
allele-specific RNAi, triggered through the delivery of mutant
Gars–targeted artificial microRNA (miRNA) expression cassettes
packaged within self-complementary adeno-associated viral
vectors, serotype 9 (scAAV9).

Results

We sought to demonstrate the therapeutic efficacy of a patientspecific RNAi-based gene therapy in a “humanized” mouse model
expressing a patient-specific GARS mutation introduced into
the mouse Gars gene. A 13-month-old female presented with
impaired motor skills and regressing motor milestones involving both upper and lower extremities. She was able to sit independently, but used her arms to stabilize herself in a sitting position (tripod sitting). Increased lumbar lordosis was also noted at
first examination. Dysmorphic features were noted, likely due
to generalized muscle atrophy. Extraocular muscle function was
normal. Deep tendon reflexes were difficult to obtain or absent,
and she showed general, marked decreases in muscle tone, head
lag, axillary slippage, mild tongue atrophy, ligamentous laxity
in the hands and feet, and excessive retraction of the chest wall.
The patient was delivered by C-section at 37 weeks gestation

RESEARCH ARTICLE

after a pregnancy complicated by hypertension. She required
oxygen supplementation and had mild neonatal jaundice, but
was discharged after 5 days. Newborn screening was normal,
and motor development was probably normal at first, with the
ability to reach for objects at 4 months and stand with support at
8 months. There was no history of seizures, and cognitive development was uncompromised.
Muscle biopsy at 15 months was indicative of neurogenic
changes consistent with motor neuronopathy or neuropathy. This
included marked atrophy of type I and II fibers with isolated, clustered, and fascicles of hypertrophied type I myofibers. There was
no evidence of myofiber necrosis, degeneration, or regeneration,
nor of dystrophic or inflammatory myopathy. Electromyography
and nerve conduction studies were consistent with motor neuron
disease: motor nerve conduction velocities were reduced (26 m/s
upper and 15 m/s lower), while sensory examination revealed no
deficits, including sensory nerve conduction (2.0 milliseconds
latency and 46 μV at her wrist). At 20 months, MRI of the brain
and cervical spinal cord were normal, as was an analysis of the
cerebrospinal fluid. She did not display evidence of further decline
and did not regress in any areas. Indeed, she seemed slightly
stronger overall with no problems swallowing or drinking. Cranial
nerves were intact and there was no evidence of tongue fasciculation. However, motor examination revealed decreased muscle
mass and tone, axillary slippage, flaccid lower limbs, and higharched feet. She could still sit independently using her upper limbs
for support, and displayed head lag and an inability to stand on her
own. A diagnosis of neuronopathy was suspected; however, there
was no reported family history of this phenotype, and the patient’s
nonidentical twin brother was unaffected.
A recessive or dominant de novo inheritance pattern was predicted. Patient DNA was extracted and subjected to both targeted
and unbiased screening strategies. This revealed 2 full-length,
WT copies of the SMN1 gene and 1 copy of SMN2, ruling out spinal muscular atrophy types I through III. Furthermore, targeted
analysis did not reveal mutations in IGHMBP2 or UBE1, ruling
out recessive, distal spinal muscular atrophy and X-linked spinal
muscular atrophy type II, respectively. Whole-exome sequencing
analysis revealed that the patient is heterozygous for a 12-nucleotide deletion in exon 8 of the glycyl-tRNA synthetase (GARS)
gene (c.894_905del; GenBank NM_002047.2). This mutation
resulted in the deletion of 4 amino acids in the GARS protein
(p.Glu299_Gln302del; NP_002038.2), hereafter referred to as
ΔETAQ. No other potentially pathogenic variant was identified
at another locus that could potentially explain the severity of
the neuropathy by a dual molecular diagnosis (24). Neither parent carries the identified GARS mutation, nor does the patient’s
twin brother, indicating a de novo mutation. GARS functions to
ligate glycine onto cognate tRNA molecules. The ΔETAQ GARS
mutation results in the deletion of 4 amino acid residues that
are conserved from human to bacteria and that reside within the
glycine-binding pocket (Figure 1A and ref. 25).
To determine whether the ΔETAQ GARS mutation affects
mRNA expression or stability, we performed RNA-Seq in patient
primary dermal fibroblasts. These analyses revealed an even distribution of WT (53.7%) and ΔETAQ (46.3%) RNA-Seq reads, indicating that ΔETAQ GARS does not dramatically affect transcript
jci.org   Volume 129   Number 12   December 2019
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Figure 1. In vitro characterization of ΔETAQ mutation. (A)
The position and evolutionary conservation of the ΔETAQ
(red) and P234KY (green) GARS mutations. (B) Initial
aminoacylation rates (pmol/min) of WT (black), P234KY
(green), and ΔETAQ (blue) GARS were plotted against tRNA
concentrations and fit to the Michaelis-Menten equation.
(C) Representative cultures of yeast strains lacking GRS1 to
test for growth in the presence of each mutation (ΔETAQ or
P234KY) modeled in the human GARS open reading frame.
(D) WT, P234KY, or ΔETAQ GARS was expressed (with a V5
tag) and tested by immunoprecipitation with an anti-NRP1
antibody to detect aberrant interactions. Western blots
were performed with anti-NRP1 and anti-V5 antibodies.
Immunoprecipitation (IP), negative control (IgG), and input
experiments are indicated.

levels (Supplemental Figure 1A; supplemental material available
online with this article; https://doi.org/10.1172/JCI130600DS1).
To examine GARS protein levels, we performed Western blot
analysis on whole-cell lysates from patient cells compared with a
control primary dermal fibroblast cell line (i.e., bearing no GARS
mutations). These experiments did not reveal an observable difference in total GARS protein levels in the affected fibroblasts
compared with the control cell line (Supplemental Figure 1B). We
next performed aminoacylation assays and yeast complementation tests to assess whether ΔETAQ GARS affects the primary
activity of the enzyme. Analysis of the initial rate of aminoacylation as a function of the tRNA substrate concentration showed
that ΔETAQ GARS retained less than 0.01% aminoacylation
activity (Figure 1B and Supplemental Table 1) compared with WT
GARS. In parallel, we tested the previously described mouse allele
P234KY (P278KY in the mouse, where 234 is numbered without
the 44–amino acid mitochondrial targeting sequence), given its
nearby location in the protein (Figure 1A and ref. 22). Although
the P234KY allele showed activity in assays with saturating tRNA
and glycine substrate concentrations (22), a reevaluation of kinetic
properties under Michaelis-Menten conditions showed a marked
decrease in enzyme activity (Figure 1B and Supplemental Table 1).
The reduced function of the ΔETAQ allele was further supported
by the failure of this mutant protein to complement ablated cellular growth associated with deletion of the yeast ortholog GRS1
(Figure 1C). Data from this latter assay also support the loss-offunction effect associated with P278KY Gars (Figure 1C), and are
consistent with the failure of the mouse P278KY allele to complement an RNA-null allele of Gars (22).
Neuropathy-associated GARS mutations bind inappropriately
to NRP1 (23). To test for binding between ΔETAQ GARS and NRP1,
we expressed V5-tagged WT, P234KY, and ΔETAQ GARS in the
mouse NSC-34 cells. After immunoprecipitation with an anti-NRP1
antibody, Western blots were performed using an anti-V5 antibody. In contrast to the reported strong association with P234KY
5570
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GARS (23), the V5 signal associated with ΔETAQ GARS was much
weaker, although stronger than that of WT GARS, which showed
no V5 signal (Figure 1D). No interaction between ΔETAQ GARS
and NRP1 was detected in unbiased mass spectrometry analyses
of proteins immunoprecipitated from mouse neuroblastoma
(MN1) cells expressing FLAG-tagged WT or V5-tagged ΔETAQ
GARS (Supplemental Figure 2). In sum, ΔETAQ showed a
severe defect in aminoacylation activity and, at best, a slight
aberrant interaction with NRP1.
To definitively validate the pathogenicity of ΔETAQ GARS in
vivo, we engineered a mouse model in which the mutation was
introduced into the mouse Gars gene (GarsΔETAQ/+) (see Methods).
For subsequent preclinical studies, GarsΔETAQ/+ mice were crossed
to GarshuEx8/huEx8, a second mouse model engineered to harbor
a “humanized” WT GARS exon 8 replacement in the mouse
gene. The 50 amino acids encoded by exon 8 are 100% identical between mouse and human, although there are silent singlenucleotide differences between the mouse and human Gars/GARS
exon 8 that could affect allele specificity of gene silencing. Our
attempts to introduce these additional human changes when engineering the ΔETAQ allele were unsuccessful, and only the 12-bp
deletion was incorporated.
This breeding produced a cohort of GarsΔETAQ /huEx8 mice with
GarshuEx8/+ littermate controls. Reverse transcriptase PCR using
cDNA isolated from sciatic nerve of heterozygous mice revealed
coexpression of ΔETAQ and WT Gars (Supplemental Figure 3A).
A Western blot analysis of brain homogenates using a polyclonal
anti-GARS antibody confirmed that ΔETAQ Gars did not alter
GARS protein levels, suggesting that a stable transcript and protein products are produced from the ΔETAQ allele, as in patient
fibroblasts (Supplemental Figure 3B).
At 12 weeks of age, GarsΔETAQ/huEx8 and GarshuEx8/+ littermates
were evaluated for features of primary neuropathy, as observed
in other mouse models of CMT2D (22, 26). GarsΔETAQ/huEx8 mice
displayed overt neuromuscular dysfunction and a reduction in

The Journal of Clinical Investigation  
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Figure 2. In vivo characterization of the ΔETAQ GARS variant. (A) GarsΔETAQ/huEx8 mice and littermate controls were weighed at 12 weeks. GarsΔETAQ/huEx8 mice
were significantly lighter, weighing 19 ± 1.9 g (P = 0.0006, n = 8), compared with GarshuEx8/+ controls, which weighed 27.4 ± 4.84 g (n = 7). (B) Gross motor
performance in GarsΔETAQ/huEx8 mice was quantified using a wire hang test. While GarshuEx8/+ mice averaged 55 ± 9.57 seconds before letting go, GarsΔETAQ/huEx8
mice (n = 8) fell after only 17.3 ± 11.3 seconds. (C) Myelinated axon number in the motor branch of the femoral nerve was reduced by 21% from 551 ± 45 axons
in littermate controls to 438 ± 92 axons in GarsΔETAQ/huEx8 (n = 6 mice per genotype). (D) Axon diameters were reduced, as shown in a cumulative histogram (P
< 0.0001, Kolmogorov-Smirnov test, average diameter 1.6 ± 0.8 μm, n = 6), in comparison with Gars+/huEx8 littermates (3.3 ± 2.198 μm, n = 6). (E) Representative images of femoral motor nerve cross sections. (F) Nerve conduction velocity (NCV) was reduced from 35 ± 6.29 m/s in littermate controls to 13.5 ± 4.1
m/s in GarsΔETAQ/huEx8 mice (P = 0.0002, n = 6 GarsΔETAQ/huEx8, n = 7 GarshuEx8/+). (G) Neuromuscular junctions (NMJs) from the plantaris muscle showed partial
innervation and denervation, scored based on the overlap between pre- and postsynaptic staining. (H and I) Representative images of NMJ morphology and
innervation are shown. Differences in body weight, grip strength, conduction, and axon number between genotypes were statistically evaluated using a
2-way Student’s t test; axon diameter was evaluated by a Kolmogorov-Smirnov test. Significant difference in overall percentage NMJ innervation was determined by 2-way ANOVA with Tukey’s honestly significant difference (HSD) post hoc comparisons. For all analyses, *P < 0.05, ***P < 0.001, ****P < 0.0001
represent post hoc significance between genotypes. Values are mean ± SD. Scale bars: 100 μm (E); 50 μm (H, I).

body weight (P = 0.0006) and grip strength (P = 0.0002) compared
with GarshuEx8/+ controls (Figure 2, A and B). Histological changes
in GarsΔETAQ/huEx8 mice were observed in cross sections of the motor
branch of the femoral nerve, including an overall decrease in axon
number (P = 0.0293) and axon diameter (P < 0.0001) (Figure 2,
C–E). The axon diameters were reduced in the sensory branch
of the femoral nerve, but the number of myelinated axons was
unchanged (Supplemental Figure 4, A and B). Nerve conduction

velocities (NCVs) were reduced by 62%, falling from 35 ± 6.29
m/s in control animals to 13.5 ± 4.1 m/s (P = 0.0002) in the sciatic
nerve in mutant mice (Figure 2F). This decrease was consistent
with other mouse Gars neuropathy models and with some patients
with GARS-mediated peripheral neuropathy (CMT2D). There was
a concomitant disruption of neuromuscular junctions (NMJs) in
distal muscles. While postsynaptic receptor fields of NMJs in the
plantaris muscle were fully occupied by motor nerve terminals
jci.org   Volume 129   Number 12   December 2019
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shuttle designed to specifically target
ΔETAQ transcripts for degradation
(Figure 3, A and B, and Supplemental Figure 5). We designed 6 different mir-30–based artificial miRNA
shuttles (mi.ΔETAQ1–6) with a
mature guide strand designed to
specifically target both human and
mouse mutant Gars ΔETAQ mRNA
for degradation (Figure 3B and Supplemental Figure 5). To identify
a lead miRNA shuttle, we cloned
each mi.ΔETAQ sequence into a U6
promoter–driven expression cassette.
These were used in an initial in vitro
dual-luciferase screening assay (31),
in which we cloned the ΔETAQ or WT
Gars target sequences into the 3′-UTR
of sea pansy (Renilla reniformis) luciferase and used firefly luciferase as
a standard. Knockdown efficiency
and disease allele specificity were
tested following cotransfection of
the reporter plasmid and each U6.mi.
ΔETAQ shuttle (or a control vector)
into HEK293 cells. The most effective
construct (mi.ΔETAQ5, now referred
to as mi.ΔETAQ) (Figure 3, B and C)
was cloned into a self-complementary adeno-associated viral vector
Figure 3. Generation of ΔETAQ-targeting miRNA shuttles. (A) Therapeutic miGARS miRNAs utilize naturally
(serotype 9; scAAV9) for in vivo
occurring RNAi biogenesis and gene silencing pathways in targeting cells. Each miGARS or control sequence
delivery (Figure 3B and Supplemen
was cloned as a DNA template downstream of a U6 promoter and then delivered to cells via plasmid transfection (in vitro) or within scAAV9 particles in vivo (depicted here). Once in the target cell nucleus, primary miRNA tal Figure 5).
To establish the proof of princonstructs are transcribed and then processed by the RNAses DROSHA and DICER and the nuclear export
factor exportin-5 (Exp5). The mature antisense strand (red line) incorporates into the RNA-induced silencing
ciple of this approach in vivo, we
complex (RISC) to elicit sequence-specific degradation of the mutant Gars mRNA. (B) MiRNAs were tested
tested whether the reduction of
in vitro by cotransfection of HEK293 cells with U6-miGARS, or control, plasmid miRNA and a dual-luciferase
mutant Gars expression before disreporter plasmid containing 1 of 4 target genes cloned into the 3′-UTR of Renilla luciferase: WT human GARS,
ease onset could prevent the neur
human ΔETAQ GARS, WT mouse Gars, or the mouse Gars gene containing the same ETAQ deletion. Target
ΔETAQ/huEx8
mice. A dose
gene silencing was then determined by measurement of the ratio of Renilla to firefly luciferase. The values are opathy in Gars
reported as mean ratios ± SEM. (C) The sequence of the guide strand of the lead mi.ΔETAQ and its compleof approximately 2.6 × 1011 viral
mentarity to both the WT and ΔETAQ GARS gene. The 4–amino acid deletion is shown in red. Base pairing
genomes (vg) of scAAV9.mi.ΔETAQ
between the miRNA and target genes is shown with vertical lines, with red lines indicating wobble G-U bonds
or scAAV9.mi.LacZ (expressing a
present in RNA duplexes.
control miRNA targeting the E.
coli LacZ gene) was delivered with
an intracerebroventricular (i.c.v.)
in control littermates, 60% ± 14.2% of NMJs were partially occuinjection at postnatal day 0–1 (P0–P1) to GarsΔETAQ/huEx8 and litpied and 8.5% ± 9.9% were completely denervated in ΔETAQ
termate control (GarshuEx8/huEx8) pups. All mice were evaluated
mice (Figure 2, G–I). Defects in NMJ innervation were evident at
for established signs of neuropathy at 4 weeks of age, approxi6 weeks of age, and examples of fully innervated, partially innermately 1.5 weeks after the initial onset of overt signs of neuropvated, and denervated junctions are shown in Supplemental Figathy. GarsΔETAQ/huEx8 mice treated with scAAV9.mi.ΔETAQ showed
ure 4, C–G, and resemble those in previously reported Gars mice
improvement in a wire hang test of grip strength, increased
(22, 26–28). Thus, GarsΔETAQ/huEx8 mice display primary features of
muscle-to-body-weight (MW/BW) ratios, and improved sciatic
nerve conduction velocity (NCV) compared with control-treated
peripheral neuropathy similar to other established mouse models
ΔETAQ mice (Figure 4, A–C). Examination of cross sections of
of CMT2D, confirming that the ΔETAQ GARS mutation is pathothe motor branch of the femoral nerve revealed that scAAV9.
genic (22, 26, 29, 30).
mi.ΔETAQ treatment prevented the axon loss and lessened the
To test whether allele-specific knockdown of mutant GARS
decrease in axon diameters observed in untreated and scAAV9.
using RNAi would be efficacious, we first engineered a miRNA
5572
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Figure 4. scAAV9.mi.ΔETAQ treatment prevents the onset of neuropathy in ΔETAQ mice. (A–C) Neonatal scAAV9.mi.ΔETAQ treatment significantly
prevented deficits in gross motor performance quantified by the wire hang test (P = 0.0001) as well as reductions in MW/BW ratios (P = 0.0315) and NCVs
(<0.0001), in comparison with untreated or vehicle-treated GarsΔETAQ/huEx8 mice. (D–F) Quantification of axon number and axon size indicated that scAAV9.
mi.ΔETAQ could partially prevent axon loss (P = 0.0272) and reductions in axon diameter (P ≤ 0.0001) in comparison with scAAV9.mi.LacZ-treated ΔETAQ
mice, as shown in cross sections of the motor branch of the femoral nerve. Axon diameter was analyzed using a Kolmogorov-Smirnov normality test, while
all other outcome measures were analyzed using a 2-way ANOVA with Tukey’s HSD post hoc comparisons. *P < 0.05, ****P < 0.0001 represent post hoc
significance between scAAV9.mi.ΔETAQ- and scAAV9.mi.LacZ-treated ΔETAQ mice. Values are mean ± SD. Scale bars: 100 μm. Untreated GarshuEx8/huEx8,
n = 4; mi.LacZ-treated GarshuEx8/huEx8, n = 3; scAAV9.mi.ΔETAQ-treated GarshuEx8/huEx8, n = 5; mi.LacZ-treated GarsΔETAQ/huEx8, n = 5; and scAAV9.mi.ΔETAQtreated GarsΔETAQ/huEx8, n = 5.

mi.LacZ-treated ΔETAQ mice (Figure 4, D–F). Injection with
scAAV9.mi.ΔETAQ (or scAAV9.mi.LacZ) did not cause adverse
effects in control mice. Collectively, these data provide the proof
of concept that allele-specific knockdown using virally delivered
RNAi may be an effective approach for treating CMT2D.
We next delivered scAAV9.mi.ΔETAQ to cohorts of both earlysymptomatic (5-week-old) and late-symptomatic (9-week-old)
GarsΔETAQ/huEx8 mice and littermate controls via a single intrathecal injection into the lumbar spinal cord. When left untreated,
5-week-old early-symptomatic GarsΔETAQ/huEx8 mice undergo active
axon loss, while axon loss slows and muscle atrophy accelerates in
9-week-old late-symptomatic ΔETAQ mice.
The scAAV9.mi.ΔETAQ-treated early-symptomatic GarsΔETAQ/huEx8
mice displayed enhanced grip strength and increases in body weight
starting at about 5 weeks after treatment compared with untreated
controls (Figure 5A). When analyzed for primary signs of neuropathy at 7 weeks after treatment, early-symptomatic GarsΔETAQ/huEx8
mice also exhibited significant increases in MW/BW ratios, NCV,
and NMJ innervation and a reduction in axon loss but no improvement in axon size compared with untreated GarsΔETAQ/huEx8 mice
(Figure 5, B–D and F). When treated with scAAV9.mi.ΔETAQ at
9 weeks of age, GarsΔETAQ/huEx8 mice gained weight and displayed
enhanced grip strength starting at 5–7 weeks after treatment (Figure 5A). While MW/BW ratios were not improved and axon loss

and atrophy were not prevented, scAAV9.mi.ΔETAQ did improve
NCV and NMJ innervation (Figure 5, B, E, and F). Analysis of mRNA
from sensory dorsal root ganglia (DRGs), which are also transduced
by scAAV9, via pyrosequencing indicated that mutant Gars mRNA
levels were significantly reduced in scAAV9.mi.ΔETAQ-treated
mice (Supplemental Table 2).
We also evaluated possible off-target effects of the RNAi. In
addition to prediction programs, we also empirically tested for
gene expression changes and found 325 genes that were altered
in their expression with an FDR less than 0.05 based on RNASeq of patient fibroblasts transfected with the mi.ΔETAQ construct in comparison with eGFP transfection as a control. The
physiological significance of these changes is unknown, and the
transcriptome of fibroblasts will be only partially shared with
that of neurons. To evaluate possible adverse effects in vivo, WT
mice were treated with the same dose of vector by intrathecal
injection (30 seven-week-old female mice comprising 3 groups:
10 mi.ΔETAQ treated, 10 mi.LacZ treated, and 10 untreated).
No adverse effects other than a mild increase in germinal center activity in the spleen were seen 10 weeks after treatment
after full necropsy and evaluation by a veterinary pathologist
blinded to treatment.
We confirmed the efficacy of allele-specific knockdown in
a second mouse model of CMT2D, GarsP278KY/+ (22). A miRNA
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Figure 5. Post-onset therapeutic effects of scAAV9.mi.ΔETAQ. (A) Reduction in mutant Gars expression improved grip strength and increased body
weight in early- and late-symptomatic GarsΔETAQ/huEx8 mice. Mi.ΔETAQ-treated
early- and late-symptomatic GarsΔETAQ/huEx8 mice exhibited enhanced grip
strength and significant increases in body weight starting at approximately
5 weeks after treatment. When evaluated at 7 weeks after treatment for
signs of neuropathy, these data correlate with trending increases in MW/
BW ratios and significant improvements in NCV in mi.ΔETAQ-treated
late-symptomatic GarsΔETAQ/huEx8 mice. (B–D) Early-symptomatic GarsΔETAQ/huEx8
mice treated with mi.ΔETAQ displayed significantly higher MW/BW ratios
and faster NCVs (B), most likely resulting from the greater number of motor
axons observed in cross sections of the motor branch of the femoral nerve,
although improvement in axon diameter was not observed (C and D). (E)
Prevention of axon loss was not observed in mi.ΔETAQ-treated latesymptomatic GarsΔETAQ/huEx8 mice. (F) Both early- and late- symptomatic
overall displayed significant increases in NMJ innervation. Data were analyzed
using a 1-way ANOVA followed by Tukey’s HSD post hoc comparisons. Significant changes in axon diameter (E) were determined with a KolmogorovSmirnov test. *P < 0.05, **P < 0.01, ***P < 0.001 represent post hoc significance between mi.LacZ-treated and scAAV9.mi.ΔETAQ-treated GarsΔETAQ/huEx8
mice. #Significant difference in fully innervated NMJs; §significant difference
in partially innervated NMJs; †significant difference in denervated NMJs.
Late-symptomatic cohort: mi.LacZ-treated GarshuEx8/huEx8, n = 5–7; scAAV9.
mi.ΔETAQ-treated GarshuEx8/huEx8, n = 3–5; mi.LacZ-treated GarsΔETAQ/huEx8,
n = 6; and scAAV9.mi.ΔETAQ-treated GarsΔETAQ/huEx8, n = 7. Early-symptomatic
cohort: GarshuEx8/huEx8, n = 6–7; scAAV9.mi.ΔETAQ-treated GarshuEx8/huEx8,
n = 3–5; mi.LacZ-treated GarsΔETAQ/huEx8, n = 7; and scAAV9.mi.ΔETAQ-treated
GarsΔETAQ/huEx8, n = 9–11. Values are mean ± SD. Scale bars: 100 μm.

i.c.v. injection (Supplemental Figure 8), consistent with the need
to target the nervous system and not peripheral tissues.
The beneficial effects of i.c.v. delivery of the high dose (1 ×
1011 vg) of scAAV9.mi.P278KY at P0 lasted at least 1 year (Figure 7). Treated mice maintained more normal body weights than
sham-treated controls (Figure 7A). They also maintained their
normal performance in the wire hang test (Figure 7B). One year
after treatment, the GarsP278KY/+ mice did not show signs of muscle
atrophy, reduced NCV, axon loss, or axon atrophy (Figure 7, C–G).
Thus, consistent with the perdurance of AAV9, a single dose at
birth prevented neuropathy for at least 1 year.
The outcomes in post-onset studies in both genotypes were
variable, likely because of the challenges in intrathecal delivery
in mice. However, the knockdown efficacy of mutant Gars transcripts within DRGs (Supplemental Tables 2–4) correlated with
therapeutic outcomes within both post-onset studies (Supplemental Figure 9, A, B, E, and F). This correlation was stronger with
mRNA isolated from DRGs than when outcomes were compared
with mutant Gars mRNA levels in liver, another tissue transduced
by scAAV9 (Supplemental Figure 9, C, D, G, and H). This is consistent with the benefit coming from the transduction of cells with
direct delivery to the nervous system and not from transduction of
peripheral organs.

Discussion

shuttle targeting the mouse P278KY allele was optimized as before
and packaged into scAAV9 (Supplemental Figure 6). As with the
ΔETAQ vector, improvements were observed in neonatal, earlyand late-symptomatic GarsP278KY/+ mice that were treated with 1
× 1011 vg of scAAV9.mi.P278KY delivered by i.c.v. (neonates) or
intrathecal (adults) injection (Figure 6 and Supplemental Figure
7). GarsP278KY/+ mice treated with the therapeutic vector at P0–P1
showed WT performance in the wire hang test (Figure 6A), and
did not show signs of muscle atrophy, reduced NCV, or axon loss
when examined at 4 weeks of age (Figure 6, B–D). Axon diameters in the motor branch of the femoral nerve and innervation at
the NMJ were both improved over untreated or scAAV9.mi.LacZtreated mice, but were not preserved to WT levels (Figure 6, E–H).
No adverse effects were noted in WT mice treated with this vector.
When treated after the onset of disease at 5 or 9 weeks of age, these
mice improved in their grip strength and body weights over the next
7 weeks to a greater extent than mice treated with the lacZ vector
(Supplemental Figure 7). While muscle atrophy was reduced with
treatment at 5 weeks of age, it was not improved with treatment at 9
weeks, and NCV was not improved at either time point (Supplemental Figure 7). However, innervation at the NMJ was improved at both
ages (Supplemental Figure 7).
The therapeutic effects of scAAV9.mi.P278KY were dose
dependent, and were greater with i.c.v. delivery compared with
a systemic, i.v. injection delivering the same total dose (Supplemental Figure 8). With i.c.v. delivery, doses including 1 × 1010, 5 ×
1010, and 1 × 1011 vg all showed dose-dependent improvement over
untreated mice, with 1 × 1011 achieving near-complete prevention
of the neuropathy (Figure 6 and Supplemental Figure 8). Delivering 1 × 1011 vg systemically by i.v. injection produced benefit comparable to 1 × 1010 vg delivered directly to the nervous system by

In this study we examined a new de novo variant of GARS,
ΔETAQ, identified in a patient with an early-onset motor neuropathy. Although not unprecedented, the severity and onset of
this case are atypical for CMT2D (14). Biochemical characterization of the mutation revealed a loss of activity in the charging of
glycine onto tRNAGly, consistent with other pathogenic alleles of
GARS (18). However, in contrast to other pathogenic alleles (23),
the mutant protein does not strongly bind to NRP1. Given the
atypical clinical presentation and biochemical properties of the
ΔETAQ variant, we confirmed its pathogenicity by introducing
the same change into the mouse Gars gene. Mice carrying this
dominant mutation developed a severe, early-onset peripheral
neuropathy, confirming that it is indeed disease-causing. We
next developed an allele-specific-knockdown vector to target
mutant Gars transcripts while leaving the WT Gars mRNA intact.
RNAi sequences were optimized in vitro and cloned into a miR30 shuttle construct driven by a U6 promoter, which was packaged into scAAV9 for in vivo delivery. Treatment of the mouse
model at birth by i.c.v. injection was able to largely prevent the
onset of neuropathy, and delivery by intrathecal injection after
the onset of symptoms still had benefit, though the degree of
benefit decreased as delivery of the treatment was delayed.
These results were confirmed in a second mouse model of
CMT2D, carrying a mutation (P278KY) not found in patients.
In these mice, an allele-specific knockdown vector delivered
as above produced similar benefit, both before and after onset.
These effects were dose dependent and persisted for at least 1
year. The improvement in neuropathy phenotypes correlated
with the degree of knockdown of the mutant Gars mRNA. Thus,
our findings support the feasibility of virally delivered RNAi for
allele-specific knockdown as a treatment strategy for a dominant
neuropathy caused by mutations in an essential gene.
jci.org   Volume 129   Number 12   December 2019
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Figure 6. Reduction of mutant Gars by RNAi prevents neuropathy in GarsP278KY/+ mice. (A and B) Neonatal scAAV9.mi.P278KY treatment prevented deficits in
gross motor performance quantified at 4 weeks of age by the wire hang test (P = 0.0001) (A) and reductions in MW/BW ratios (P = 0.0463) (B) in comparison
with untreated and vehicle-treated P278KY mice. (C) NCVs were also significantly improved (P ≤ 0.0001) in treated P278KY mice. (D) Quantification of axon
number within cross sections of the motor branch of the femoral nerve showed that while axon number was reduced by 17% in control-treated P278KY mice,
axon counts in scAAV9.mi.P278KY-treated P278KY mice (589 ± 15 axons) were similar to those in untreated control littermates (600 ± 11 axons). (E) scAAV9.
mi.P278KY treatment also restored the presence of large-diameter axons; average axon diameter was 1.98 ± 4.47 μm in control-treated P278KY mice, 2.71 ±
3.71 μm in scAAV9.mi.P278KY-treated P278KY mice, and 3.84 ± 3.74 μm in untreated Gars+/+ mice. (F) Representative images of cross sections of the motor
branch of the femoral nerve isolated from untreated Gars+/+, GarsP278KY/+, and scAAV9.mi.P278KY-treated GarsP278KY/+ mice. (G) Representative images of NMJ
morphology isolated from plantaris muscle. (H) While over 70% of the NMJs were partially or completely denervated in control-treated GarsP278KY/+ mice by 4
weeks of age, less than 30% of NMJs showed any degree of denervation in scAAV9.mi.P278KY-treated GarsP278KY/+ mice. Numbers for all outcome measures:
untreated Gars+/+, n = 5; control-treated Gars+/+, n = 4; scAAV9.mi.P278KY-treated Gars+/+, n = 8; untreated GarsP278KY/+, n = 6; control-treated GarsP278KY/+, n = 5;
scAAV9.mi.P278KY-treated GarsP278KY/+, n = 7. Significance in A–D and H was determined by 2-way ANOVA with Tukey’s HSD post hoc comparisons. Significant changes in axon diameter (E) were determined with a Kolmogorov-Smirnov test. *P < 0.05, ****P < 0.0001 represent post hoc significance between
mi.LacZ-treated and scAAV9.mi.P278KY-treated GarsP278KY/+ mice. Values are mean ± SD. All scale bars: 100 μm.
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Figure 7. Long-term therapeutic effects of
neonatal scAAV9.mi.P278KY treatment. (A
and B) scAAV9.mi.P278KY-treated P278KY
mice displayed increases in body weight (A)
starting at 24 weeks after treatment and in
grip strength (B) throughout the course of 1
year compared with vehicle control–treated
P278KY mice. (C and D) When evaluated for
primary signs of neuropathy at 1 year after
treatment, treated P278KY mice exhibited
greater MW/BW ratios (C) and faster NCVs
(D). (E–G) scAAV9.mi.P278KY treatment
could preserve all populations of axons in
the motor branch of the femoral nerve at
1 year after treatment. Significance in A
and B was determined by 1-way ANOVA
with Tukey’s HSD post hoc comparisons.
Significance in C, D, and F was determined
by 2-way ANOVA with Tukey’s HSD post
hoc comparisons. Significant changes in
axon diameter (G) were determined with a
Kolmogorov-Smirnov test. Mi.LacZ-treated
Gars+/+, n = 3; scAAV9.mi.P278KY-treated
Gars+/+, n = 3; mi.LacZ-treated GarsP278KY/+,
n = 5; and scAAV9.mi.P278YK-treated
GarsP278KY/+, n = 7. Values are mean ± SD.

The disease mechanism through which mutant forms of
GARS cause CMT2D is not clear. Variants of GARS that result in
neuropathy impact the enzymatic activity of the protein to varying
degrees. Since alleles that do not produce a mutant protein do not
cause a dominant disease in mice or humans, a loss-of-function
mechanism underlying the neuropathy would have to be through a
dominant-negative mechanism. Alternatively, neomorphic gainof-function activities are consistent with findings in mouse and
Drosophila models (20, 32). Mutant forms of GARS bind to NRP1,
an important neurodevelopmental receptor that transduces both
VEGF and semaphorin signals, whereas WT GARS does not bind
NRP1 (23). This aberrant interaction interferes with VEGF binding, possibly constituting a pathogenic neomorphic activity of the
mutant protein. However, our finding that the ΔETAQ form of
GARS does not have a strong interaction with NRP1 indicates that
while this mechanism may still contribute to the disease, it is not

essential for pathogenicity. Importantly, our allele-specific knockdown approach applies equally well to a dominant-negative or a
neomorphic mechanism.
Our results also serve as a preclinical demonstration of the
feasibility of RNAi-mediated allele-specific knockdown as a
therapeutic strategy. Pre-onset treatments were able to almost
completely prevent the neuropathy. This provides strong proofof-concept data for the effectiveness of knocking down mutant
GARS. Post-onset treatment still provided benefit, though this
was less complete and diminished the longer treatment was
withheld. The post-onset treatment may stop or slow the progression of axon loss. This is best demonstrated by the reduction in axon loss seen in ΔETAQ mice treated at 5 weeks of age
compared with untreated mutant mice (Figure 5D), but there
was no similar reduction with treatment at 9 weeks of age (Figure 5E), an age by which most of the axons have already degenjci.org   Volume 129   Number 12   December 2019
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erated. Even with axon loss, some of the residual benefit may
come from improved synaptic transmission at NMJs, consistent with the improved innervation and with previous findings
that synaptic transmission is progressively impaired in Gars
mutant mice (28).
Another important consideration for the translational potential of this approach is whether we can achieve sufficient allelic
specificity with single–base pair mutations. The mutations that
we targeted here differed from WT sequence by 5 (P278KY) or
12 (ΔETAQ) bp, making them relatively good targets for specific
RNAi sequences. Allele specificity of RNAi for single-nucleotide differences will depend on surrounding local sequence, but
is precedented, and efficiency can be improved by addition of
additional mismatches to the RNAi sequence (33–35). Therefore,
a similar allele-specific knockdown strategy may be effective for
additional alleles of GARS. An alternative strategy that would
apply equally to any allele of GARS would be to knock down all
GARS transcripts, mutant and WT, using a nonspecific GARS
RNAi, and, in the same vector, provide an RNAi-resistant WT
cDNA. This strategy has been used for α1-antitrypsin (36). Other
strategies, such as allele-specific antisense oligonucleotides or
allele-specific CRISPR/Cas9 gene editing, could also be used
to silence mutant GARS alleles while preserving WT GARS, but
would require additional development.
The reduced efficacy of the treatment after the onset of
neuropathy will be complicated to dissect. It is possible that the
intrathecal delivery or reduced transduction efficiency of adult
peripheral neurons contributed to the reduced efficacy. Intrathecal delivery was chosen as it is the route of delivery in gene
therapy trials for related disorders (6). In our study, the degree of
improvement in outcomes such as NCV correlated with the extent
of the knockdown of mutant Gars relative to WT Gars transcripts
assayed by PCR in sensory DRGs (Supplemental Figures 7 and 8).
We chose to assay DRGs because they are efficiently transduced
and the sensory neurons comprise a large proportion of the tissue
mass, providing the best opportunity to assess the efficiency of the
knockdown. However, this analysis does not resolve this question
on a cell-by-cell basis, nor does it address knockdown in motor
neurons. The biodistribution of AAV9 in mice and other animals
has been previously reported (37–39), and therefore, we did not
repeat those analyses here. However, in pilot studies using AAV9GFP, we saw transduction in spinal cord and DRGs that closely
matched published results.
Despite the unknowns regarding transduction efficiency and
the extent of the knockdown, the benefit observed with post-onset
delivery is encouraging. However, it is notable that we also did not
see regeneration. The axon numbers did not increase when treatment was delivered after axon loss. Similarly, at NMJs, there was
no evidence of collateral sprouting and reinnervation of dener
vated NMJs by the remaining axons. It is unclear whether this is
due to insufficient knockdown of the mutant mRNA, or whether
the axon degeneration is irreversible. The fact that the results
were so similar in both mouse models despite the knockdown of
the P278KY allele being so efficient in vitro may suggest that the
degeneration is irreversible under normal circumstances. Therefore, the benefit of treatment after the onset of symptoms may
be limited to slowing or stopping progression, and may need to
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be combined with other strategies to promote regeneration to
achieve a better recovery of function.
In summary, these studies demonstrate how precision animal models can be used for testing personalized therapies for
rare and orphan diseases, and provide important proof of concept for RNAi-based gene therapy for this dominant disease.
This approach could be applied to other, related disorders
including other dominantly inherited peripheral neuropathies
or motor neuron diseases.

Methods

Clinical evaluation and mutation analysis. The proband was clinically
evaluated at Texas Children’s Hospital (Houston, Texas, USA). Diagnostic, whole-exome sequencing (XomeDxPlus) was performed by
GeneDx (Gaithersburg, Maryland, USA). For allele-specific Sanger
sequencing, we first isolated DNA from patient-derived primary fibroblasts. Cells were treated with trypsin according to the Wizard Genomic
DNA Purification Kit (Promega) protocol. PCR amplification was performed to obtain a 381-bp region including GARS exon 8 using PCR
SuperMix (Thermo Fisher Scientific). PCR products were cloned with
the TOPO TA Cloning Kit (Thermo Fisher Scientific). Plasmid DNA
from 6 isolated colonies was purified and Sanger-sequenced using
the PCR primers: forward 5′-GCATTGCCAAAGTAGTACTGC-3′ and
reverse 5′-CCTGACTCTGATCAGTCCAGATCG-3′.

GARS expression studies
For RNA expression studies, RNA was isolated from patient fibroblasts
using the RNeasy Mini Kit (Qiagen). cDNA was generated from 1 μg of
RNA using the High-Capacity cDNA reverse transcription kit (Applied
Biosystems). The resulting cDNA was used to amplify a 224-bp product including the ΔETAQ GARS mutation. The reaction was column
purified and checked for quality via gel electrophoresis. For nextgeneration sequencing, the product was digested and “tagmented”
using Tn5 transposase. The library was amplified by PCR using Kapa
Hifi DNA polymerase and Illumina-compatible indexing primers. Final
library fragment size and purity were determined via gel electrophoresis, and fragments were column purified and sequenced on the Illumina MiSeq with paired 155-bp reads. Overlapping reads were merged
using PEAR (version 0.9.6) and aligned using BWA MEM (version
0.7.12) to custom references containing the WT exon 7/exon 8 junction
or the ΔETAQ-containing equivalent. A custom Python script (https://
github.com/kitzmanlab/gars_burgess_2019) was used to count reads
with higher-scoring alignment to each junction. Uninformative reads
(e.g., those not spanning the mutation) were disregarded.
For fibroblast protein expression studies, proteins were isolated
in 1 mL cell lysis buffer (990 μL RIPA Lysis Buffer [Thermo Fisher
Scientific] plus 10 μL 100× Halt Protease Inhibitor [Thermo Fisher
Scientific]) and quantified using the Pierce BCA Protein Assay Kit
(Thermo Fisher Scientific). Ten micrograms of protein per sample
was analyzed via Western blot. Samples were prepared in 1× SDS
sample buffer (Thermo Fisher Scientific) plus 5 μL β-mercaptoethanol and boiled at 99°C for 10 minutes, then separated on precast
4%–20% Tris-glycine gels (Thermo Fisher Scientific), transferred
onto a PVDF membrane, and probed with the respective primary
antibody at the following dilutions in blocking solution: antiGARS 1:1000, described in ref. 17; anti-NRP1 (Abcam, EPR3113)
1:1000; and anti-actin (Sigma-Aldrich, A5060) 1:5000. Mem-
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branes were then rinsed 3 times in 1× TBST to remove unbound
antibody and incubated with the respective HRP-conjugated
secondary antibody at 1:10,000. Membranes were rinsed in 1× TBST
and exposed using SuperSignal West Dura substrate and enhancer
(Thermo Fisher Scientific).

Expression construct development
All GARS expression constructs were generated using Gateway cloning (Invitrogen). The human GARS open reading frame was amplified from human cDNA using primers with the attB1 (forward, GARS
ORF F = ATGGACGGCGCGGGGGCTGAGG) and attB2 (reverse,
GARS ORF R = TCATTCCTCGATTGTCTCT) Gateway sequences.
Entry clones were generated by recombination of PCR-purified
amplicons into the pDONR221 vector using BP clonase. Individual
WT entry clones were confirmed by sequencing. Oligonucleotides
containing sequences corresponding to each GARS mutation studied
were generated, and mutagenesis was performed using the QuikChange II XL Site-Directed Mutagenesis Kit (Stratagene). Individual
clones were sequenced to confirm each mutation and the absence of
errors. Validated entry clones were recombined into the appropriate
Gateway-compatible vector using LR clonase: pET-21a(+) for aminoacylation assays and pTM3xFLAG for coimmunoprecipitation assays.
For yeast complementation assays, human GARS was expressed from
the pYY1 expression construct containing ΔMTSΔWHEP GARS; the
pYY1 constructs were a gift from Chin-I Chien and Chien-Chia Wang
(National Central University, Taoyuan City, Taiwan).
Aminoacylation assays
WT and mutant GARS proteins were expressed in E. coli with a
C-terminal His tag and purified with nickel affinity resins (Novagen).
The T7 transcript of human tRNAGly/CCC (CCC, anticodon) was prepared and purified as previously described (40), heat-denatured
at 85°C for 3 minutes, and annealed at 37°C for 20 minutes before
use. Steady-state aminoacylation assays were monitored at 37°C in
50 mM HEPES (pH 7.5), 20 mM KCl, 10 mM MgCl2, 4 mM DTT, 2
mM ATP, and 50 μM 3H-glycine (PerkinElmer) at a specific activity
of 16,500 dpm/pmol. The reaction was initiated by mixing of GARS
enzyme (20 nM for WT enzyme and 600 nM for the ΔETAQ and
P234KY mutants) with varying concentrations of tRNA (0.3–20 μM).
Aliquots of a reaction mixture were spotted on filter paper, quenched
by 5% trichloroacetic acid, washed, dried, and measured for radioactivity using a liquid scintillation counter (LS6000SC, Beckman
Coulter Inc.). The amount of radioactivity retained on filter pads was
corrected for quenching effects to determine the amount of synthesis
of Gly-tRNAGly. Steady-state kinetics was determined by fitting of the
initial rate of aminoacylation as a function of tRNA concentration to
the Michaelis-Menten equation (41).
Yeast complementation assays
Yeast complementation assays were carried out as previously
described (17, 18). At least 2 colonies per transformation were assayed,
and each transformation was repeated at least twice.
MN1 transfections for immunoprecipitation
MN1 cells were grown at 37°C in 5% CO2 and standard growth medium
(DMEM supplemented with 10% FBS, 2 mM l-glutamine, 100 U/mL
penicillin, and 50 μg/mL of streptomycin [Invitrogen]). We obtained
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mouse MN1 cells in 2004 from Kurt Fischbeck (NIH/National Institute of Neurological Disorders and Stroke, Bethesda, Maryland, USA),
who obtained them directly from the laboratory that generated these
cells (H. Kim, University of Chicago, Chicago, Illinois, USA) (42). Cells
were transfected using Lipofectamine 2000 (Invitrogen) with 15 μg
of a plasmid to express WT or mutant GARS pTM3xFLAG per T-175
flask. Cells were incubated for 48 hours at 37°C in 5% CO2. Cells were
then harvested using 0.25% trypsin (Invitrogen), centrifuged at 805 g
for 2 minutes, and washed twice with 1× PBS.

Coimmunoprecipitation analyses
Twenty-five microliters of Dynabeads Protein G Magnetic beads
(Invitrogen) were used for each cell lysate from one T-175 flask.
Beads were washed twice in 1 mL of wash solution (0.5% BSA and
0.1% Triton X-100 in PBS) and resuspended in 1 mL of wash solution. Two micrograms anti-FLAG antibody (Sigma-Aldrich, clone
M2) was added and incubated at 4°C with gentle shaking overnight.
Transfected cells were resuspended in 1.5 mL lysis buffer (20 mM
Tris-HCl [pH 7.5], 2.5 mM MgCl2, 300 mM KCl, 0.1% NP-40, 1 mM
DTT, 0.2 mM PMSF, 1× Halt Protease Inhibitor Cocktail [EDTA free]
[Thermo Fisher Scientific]) and incubated with gentle rocking at 4°C
for 90 minutes. Cell lysates were centrifuged at 17,800 g for 5 minutes
at 4°C. The supernatant was removed and used as the input for the
immunoprecipitation (IP) reaction. Protein was quantified using the
Pierce BCA Protein Assay Kit (Thermo Fisher Scientific), and 1 mg of
protein was used as input. Expression of 3xFLAG-tagged protein in
input samples was confirmed by anti-FLAG M2 Western blotting. The
αFLAG-conjugated magnetic beads were washed twice with 500 μL
of lysis buffer, resuspended in 25 μL lysis buffer, and added to the protein sample. After 2 hours of incubation at 4°C with gentle shaking,
beads were magnetically isolated, washed 5 times with 1 mL of buffer
(20 mM Tris-HCl [pH 7.5], 2.5 mM MgCl2, 300 mM KCl, 0.1% NP-40,
1 mM DTT), and resuspended in 30–50 μL of wash buffer per 25 μL
of starting beads. Two hundred micrograms per milliliter of 3xFLAG
peptide was added to each sample and incubated at 4°C with gentle
shaking for 3 hours to elute the FLAG-tagged protein.
Mass spectrometry and bioinformatics
For mass spectrometry at the Fred Hutchinson Cancer Institute, IP
products were separated on a denaturing 4%–20% Tris-glycine gel and
silver-stained using standard protocols. Destained gel slices were used
for in-gel digestion with an ice-cold solution of 12.5 ng/μL trypsin in
50 mM ammonium bicarbonate on ice for 1 hour. The trypsin solution
was removed and replaced with 50 mM ammonium bicarbonate, and
digestion was carried out overnight at 37°C. Peptides were extracted
by the addition of 0.1% trifluoroacetic acid and light vortexing for 30
minutes followed by addition of an equal volume of 100% acetonitrile
and light vortexing for an additional 30 minutes. Desalted samples
were brought up in 10 μL of 2% acetonitrile in 0.1% formic acid, and 8
μL was analyzed by liquid chromatography/electrospray ionization tandem mass spectrometry (MS/MS) using an Easy-nLC 1000 (Thermo
Fisher Scientific) HPLC system coupled to a hybrid Orbitrap Elite
(Thermo Fisher Scientific) as previously described (43). The Orbitrap
Elite instrument was operated in the data-dependent mode, switching automatically between mass spectrometric survey scans in the
Orbitrap with MS/MS spectra acquisition in the linear ion trap. The 15
most intense ions from the Fourier transform full scan were selected
jci.org   Volume 129   Number 12   December 2019
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for fragmentation in the linear trap by collision-induced dissociation
with normalized collision energy of 35%. Selected ions were dynamically excluded for 30 seconds with a list size of 500 and exclusion
mass width of +/– 10 ppm.
For mass spectrometry at the University of Michigan (Ann Arbor,
Michigan, USA), IP products were concentrated using TCA precipitation. Two microliters of 2% sodium deoxycholate was added to 200 μL
of IP product and incubated on ice for 30 minutes. Twenty microliters
of 100% (wt/vol) TCA was added (bringing TCA to ~10%) and incubated on ice for 1 hour. The product was then centrifuged at maximum
speed at 4°C for 10 minutes, and the pellet was washed in 500 μL of
acetone and incubated on ice for 10 minutes. The acetone solution
was centrifuged at maximum speed at 4°C for 10 minutes. The resulting pellet was resuspended in 30 μL of 20 mM HEPES and 8 M urea
(pH 8.0). Three independently generated IP products for each WT,
ΔETAQ, and an untagged WT GARS sample were analyzed. MS/MS
was performed using the Orbitrap Fusion Mass Spectrometer (Thermo
Fisher Scientific).
For all mass spectrometry data analyses, the open-source proteomics search engine X! Tandem (The Global Proteome Machine
Organization) was used to match mass spectrometry data with peptide spectra. Peptide Prophet was used to validate peptide assignments (43), and Protein Prophet grouped peptides into proteins (44).
ABACUS extracted spectral counts for quantitative analysis (45).
Finally, interactions were scored to remove background, and comparisons of interacting proteins were performed to calculate the relative
fold changes for interactions between WT and ΔETAQ GARS.

Targeted assessment of NRP1-GARS interactions
NSC-34 cells (ATCC) were grown to 70% confluence before transfection. Human WT, P234KY, or ΔETAQ GARS cDNAs were subcloned
into the pcDNA6 plasmid in-frame with a V5 tag. Transfections were
performed using Lipofectamine 2000 (Invitrogen). Thirty-six hours
after transfection, cells were washed twice in PBS, scraped into PBS,
pelleted, and resuspended in Pierce IP Lysis Buffer (Thermo Fisher
Scientific) for 30 minutes and centrifuged for 7 minutes at 12,000
g; the insoluble fraction was discarded. Protein G beads (Invitrogen)
were preincubated with anti-NRP1 antibody (Abcam, EPR3113) or
rabbit IgG (Cell Signaling Technology, 2729) for 30 minutes and then
mixed with the cell lysates for overnight. Beads were then washed 3
times with buffer (100 mM NaCl, 50 mM Tris [pH 7.5], 0.1% Triton
X-100, 5% glycerol). The immunoprecipitates were fractionated by
4%–12% Bis-Tris-Plus SDS-PAGE gels (Invitrogen) and transferred
to PVDF membranes. Membranes were blocked for 1 hour with
Tris-buffered saline with Tween-20 (TBST) containing 5% nonfat dry
milk. Proteins were detected using mouse monoclonal V5 antibody
(Invitrogen, R960-25). NRP1 was detected using the same antibody
for coimmunoprecipitation. After incubation with primary antibodies,
membranes were washed and incubated with HRP-conjugated antimouse or anti-rabbit secondary antibodies (Cell Signaling Technology, 7076, 7074, respectively) followed by detection using ECL substrate (Thermo Fisher Scientific), and exposed using the FluorChem
M imager (ProteinSimple).
Cloning of allele-specific, mutant GARS–targeted miRNAs
All design rules for artificial miRNAs are previously described (46),
including: 22-nucleotide mature miRNA length, antisense comple5580
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mentarity to the target (Gars; GARS), less than 60% GC content of the
mature duplex, and guide-strand biasing, such that the last 4 nucleotides of the antisense 5′ end were A:U rich, and the last 4 nucleotides
of the antisense 3′ end were G:C rich. Mutant GARS/Gars–targeting
miRNA constructs were designed with the seed match region targeting the differing nucleotides present in the mutant Gars alleles and
intentional mismatches with WT GARS/Gars. MiRNAs were cloned
into a U6T6 expression vector (31). After in vitro testing, lead candidate U6.miRNAs were cloned into a self-complementary proviral AAV
plasmid containing a CMV-driven eGFP reporter. scAAV9 viruses
were generated and titered by the Viral Vector Core at The Research
Institute at Nationwide Children’s Hospital (Columbus, Ohio, USA).

Luciferase assays
The dual-luciferase plasmids were created in the Psicheck2 vector
(Promega), with firefly luciferase serving as a control, and the various Gars target regions cloned downstream of the Renilla luciferase stop codon. HEK293 cells were cotransfected (Lipofectamine
2000, Invitrogen) with the appropriate reporter and an individual
U6.miRNA expression plasmid in a 1:5 molar ratio. GARS silencing
was determined 24 hours after transfection, using the Dual-Luciferase Reporter Assay System (Promega). Triplicate data were averaged,
and knockdown significance was analyzed by 2-way ANOVA. Results
are presented as the mean ratio of Renilla to firefly ± SEM.
Mice
Mice were housed in the research animal facility at The Jackson Laboratory and provided with food and water ad libitum. Gars (CAST;B6GarsNmf249/Rwb; referred to as GarsP278KY/+) are previously described
(22). The official strain designations of the newly engineered mouse
models are B6;FVB-Gars<em1Rwb>/Rwb (referred to as GarshuEx8) and
B6;FVB-Gars<em2Rwb>/Rwb (referred to as GarsΔETAQ/+). Experimental cohorts used for direct comparisons consisted of littermates.
Generation of GarsΔETAQ/+) and Gars+/huEx8)models with CRISPR/Cas9
genome-editing technology
Donor constructs. For GarshuEx8/+, the mouse exon 8 sequence was
replaced with a donor vector containing the human exon 8 sequence.
The donor was a 10-kb sequence containing a 2.8-kb 5′ arm of
homology and a 7-kb 3′ arm of homology isolated from a C57BL/6J
BAC library flanking the human exon 8 sequence. For GarsΔETAQ/+,
the donor construct consisted of an single-stranded oligonucleotide
sequence spanning the first 52 bases of mouse exon 8 with short arms
of homology (see below for sequence) containing a 12-base deletion
(bases 12–23 of exon 8).
Microinjection. Preparation and microinjection of CRISPR/
Cas9 reagents were performed as previously described (47). All
components, including Cas9 mRNA (100 ng/μL; either TriLink or
synthesized by in vitro transcription), sgRNA, guides 144 and 1340
(50 ng/μL; guide sequence below), and each donor vector (20 ng/
μL plasmid DNA or 100 ng/μL single-stranded donor oligonucleotides), were injected into the male pronucleus and cytoplasm of
about 300 zygotes at the pronuclei stage. All zygotes were isolated
from superovulated FVB/NJ (JAX stock 001600, The Jackson Laboratory) females mated with C57BL/6NJ (JAX stock 005304) males.
Then, groups of 15–25 blastocysts were transferred into the uterus of
pseudopregnant females.
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The ssODN donor sequence was AGTTTACTTGTAACAGGCTTTGTTTTATTGGAAGCACATTGTCTTACTTGTAATAGACTGGTTTATTTAATTTTATAGATACTTGAGACCGGGGATTTTCtTGAATTTCAAACGACTTTTGGAATTCAAC. The sgRNA 144
sequence was AAAATTCCCTGTGCAGTTTC. The sgRNA 1340
sequence was TCAGAAATGAGATCTCACCT.
Genotyping. Transgenic mice were genotyped for the presence
of either the humanized exon 8 or ΔETAQ constructs. Genomic
DNA was prepared from tail biopsy lysed with proteinase K. Primers
HuEx8F0_F:CATAACATCACGCGTGGTTCC and HuEx8R0_R:CAAGTGTGGCGGTTTCCATC that span the 2.8-kb 5′ arm of homology to the 3′ end of Gars exon 8 and subsequent Sanger sequencing
with HuEx8R0_R were used to identify human single-nucleotide
polymorphisms in exon 8 of Gars within GarshuEx8 founders and subsequent generations. Primers ΔETAQF0_F:GGCCATAAGCATAATTTTACTGTG and ΔETAQF0_R:TACAACAGAAACAAACTGTGGTCA with subsequent Sanger sequencing with ΔETAQF0_R
were used to detect the 12-bp deletion in bases 13–24 in GarsΔETAQ/+
founders and subsequent generations.
Reverse transcriptase PCR. Primers Gars2F_CTCCCACCACTGGCAATGAC and Gars2R_CTCACTCAGCAGCAGCTCC were used
to amplify a portion of the Gars open reading frame spanning Gars
exon 8 from first-strand cDNA generated from sciatic nerve RNA isolated from Gars+/huEx8 and GarsΔETAQ/huEx8 mice. Humanized exon 8 and
ΔETAQ transcript sequences were identified with Sanger sequencing
and primer Gars2F.
Tissue lysate preparation. Whole brain samples were isolated
from animals immediately after they were euthanized by CO2 inhalation. The tissues were frozen in liquid nitrogen and stored at –80°C.
Samples were homogenized using a mortar and pestle followed by a
Dounce homogenizer in 1% NP-40 in PBS supplemented with Protease Inhibitor Cocktail Tablets (Roche), then centrifuged at 14,000 g
twice for 5 minutes at 4°C. Cleared homogenates were then sonicated
at 4°C and centrifuged again at 14,000 g for 5 minutes. Twenty micrograms of protein was then analyzed by immunoblot.
Western blot analysis. Protein lysates were resolved on MiniPROTEAN 4%–15% Tris-glycine gels (Bio-Rad) and transferred to
an Invitrolon & Immobilon-P PVDF membrane for Western blot
analysis. Membranes were blocked with 5% skim milk in TBST (1×
Tris-buffered saline, 0.1% Tween-20), and incubated overnight with
anti-GARS (rabbit; Abcam, ab42905; 1:1000 dilution) and anti-NeuN
(mouse monoclonal; Cell Signaling Technology, E4M5P; 1:1000)
diluted in blocking solution at 4°C. After three 10-minute washes in
TBST, the blots were incubated with the appropriate HRP-conjugated
secondary antibodies (PerkinElmer, NEF812, NEF822001EA) diluted
in blocking solution. After three 10-minute washes in TBST, the blots
were developed using Western Lightening Plus-ECL, Enhanced Chemiluminescence Substrate (PerkinElmer).

Assessment of axonal neuropathy in all mouse models
Grip strength was evaluated by wire hang test (20, 26) to evaluate
gross muscle strength and endurance. Nerve conduction studies,
motor nerve histology and analysis, NMJ immunofluorescence and
analysis, and body weight evaluation were completed as previously
described (20, 30). These studies were not formally blinded. First, the
Gars mice have a visible phenotype that makes blinding with respect to
genotype difficult, although mice treated at birth were often rescued
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to an extent that made them difficult to distinguish from control mice.
The primary evaluator of the in vivo mouse studies was also the only
person proficient at the intrathecal and i.c.v. injections at the time.
Therefore, although records of which mice were treated or untreated
were not immediately at hand during the analysis, this information
was available to the tester.

Neonatal delivery of scAAV9.mi.P278KY and scAAV9.mi.ΔETAQ
Before all injections of mice at P0–P1, all pups were anesthetized via
cryoanesthesia as previously described (48). Then, all i.c.v. injections
were performed using a Hamilton syringe (catalog 65460_03) with a
32-gauge needle and escalating doses of scAAV9.mi.P278KY as stated
in Supplemental Tables 2 and 3 or 2.6 × 1011 DNAse-1–resistant particles (DRPS) per mouse of mi.ΔETAQ (about 2–10 μL) diluted in sterile
PBS. All gene therapy vectors were injected in to the lateral ventricles
by positioning of the needle directly lateral to the sagittal suture and
rostral to the neonatal coronal suture. For i.v. injections, all cryoanesthetized mice were injected with 1 × 1011 DRPS per mouse directly into
the superficial temporal vein in a caudal orientation with the use of a
Hamilton syringe (catalog 7655-01) with a 32-gauge needle.
Intrathecal delivery of gene therapy constructs to post-onset mice
With the use of a Hamilton syringe (catalog 7655-01) with a 32-gauge
needle, all adult post-onset mice were injected with approximately 1
× 1011 DRPS per mouse of scAAV9.mi.P278KY or scAAV9.mi.ΔETAQ
diluted into sterile PBS (~10 μL) via an intrathecal injection by lumbar
puncture. Here, all mice were anesthetized with isoflurane and received
an injection of the proper vector into the L6 spinous process with the use
of a Hamilton syringe with a 32-gauge needle. Each vector was slowly
injected and the needle left in place for 5–10 seconds before withdrawal.
Quantification of allele-specific expression
Whole liver and lumbar DRG samples were isolated from animals
immediately after they were euthanized by cervical dislocation. The tissues were frozen in liquid nitrogen and stored at –80°C. Samples were
homogenized using a mortar and pestle followed by a Dounce homogenizer, and RNA was isolated from liver using Trizol Reagent (catalog
15596018, Thermo Fisher Scientific) and DRGs using either an RNeasy
Mini Kit (catalog 74104 and 74106, Qiagen) or a mirVana miRNA Isolation Kit (catalog AM1560, Thermo Fisher Scientific). All RNA samples
were reverse transcribed using SuperScript III First-Strand Synthesis
System (catalog 18080051). To quantify allele-specific expression of
WT and mutant GARS, EpigenDx performed pyrosequencing on the
PSQ96 HS System (Qiagen) following the manufacturer’s instructions,
using custom assays.
Statistics
Statistical tests were performed using GraphPad Prism 7 software.
A 2-tailed Student’s t test or 1-way or 2-way ANOVA followed by
Tukey’s honestly significant difference (HSD) post hoc comparisons test (as indicated in the figure legends) was used to determine significant differences between treatment groups and/or
genotypes for axon counts, conduction velocity, grip strength, and
body weight. Axon diameters were compared using nonparametric
Kolmogorov-Smirnov 2-sample and Shapiro-Wilk normality tests.
NMJ innervation status between genotypes and categories (fully
innervated, partially innervated, and denervated) was evaluated
jci.org   Volume 129   Number 12   December 2019
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with a 2-way ANOVA followed by Tukey’s HSD post hoc comparisons test. A P value less than 0.05 was considered significant.

Study approval
Clinical procedures and sequencing that went beyond standard-ofcare clinical evaluation and diagnostics were performed under the
Institutional Review Board–approved protocol H-29697, Genome
Sequencing to Elucidate the Causes and Mechanisms of Mendelian
Genetic Disorders, Baylor College of Medicine, Houston, Texas,
USA. Clinical data were obtained after written informed consent
from the proband’s parents. All mouse husbandry and experimental procedures were conducted according to the NIH Guide
for the Care and Use of Laboratory Animals (National Academies
Press, 2011) and were reviewed and approved by the Animal Care
and Use Committee of The Jackson Laboratory, Bar Harbor, Maine,
under Animal Use Summary 1026, “The formation and maintenance of neuronal synapses and circuits.”
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